High serum IgA and activated Th17 and Treg predict the efficacy of abatacept in patients with early, seropositive rheumatoid arthritis.
Abatacept
Biomarker
Precision medicine
Rheumatoid arthritis
Journal
Clinical rheumatology
ISSN: 1434-9949
Titre abrégé: Clin Rheumatol
Pays: Germany
ID NLM: 8211469
Informations de publication
Date de publication:
Sep 2021
Sep 2021
Historique:
received:
16
11
2020
accepted:
19
01
2021
revised:
15
01
2021
pubmed:
12
3
2021
medline:
14
8
2021
entrez:
11
3
2021
Statut:
ppublish
Résumé
To identify the predictive biomarkers for achieving remission with abatacept in patients with seropositive rheumatoid arthritis (RA). We enrolled patients with RA who were treated with abatacept. We compared the baseline laboratory results and longitudinal immune-phenotyping data between patients who achieved remission and those who did not achieve remission at 6 months according to the clinical disease activity index. One hundred and twenty RA patients were enrolled. In the seropositive patients with early RA (n = 24), high serum IgA levels, anti-citrullinated peptide (CCP) titers, and neutrophil counts before treatment were predictors of remission (area under the curve [AUC], 0.659, 0.741, and 0.704, respectively). Additionally, activated Th17 (aTh17) cells and activated Treg (aTreg) cells before treatment were found to be significantly higher in patients with remission compared to those without remission (2.9% vs 1.1%, P = 0.02; 34.3% vs 17%, P = 0.03, respectively). The measurement of longitudinal cell subpopulation revealed a decrease in the effector CD4 T cell population after abatacept treatment, which correlated with anti-CCP titers and neutrophil counts, and was associated with remission achievement. In seropositive patients with established RA (n = 79), high RF titers and low IFN-γ levels were associated with the good response to abatacept. Our study has shown that serum IgA levels, anti-CCP titer, and neutrophil counts are predictive biomarkers for predicting the response to abatacept in patients with seropositive and early RA and may reflect the inhibition of effector CD4 T cell subpopulations by abatacept. Key Points • Serum IgA levels and neutrophil counts are novel biomarkers for predicting the efficacy of abatacept. • Those may reflect the inhibition of effector CD4 T cell subpopulations by abatacept.
Identifiants
pubmed: 33704594
doi: 10.1007/s10067-021-05602-0
pii: 10.1007/s10067-021-05602-0
doi:
Substances chimiques
Anti-Citrullinated Protein Antibodies
0
Antirheumatic Agents
0
Immunoglobulin A
0
Abatacept
7D0YB67S97
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
3615-3626Informations de copyright
© 2021. International League of Associations for Rheumatology (ILAR).
Références
Moreland L, Bate G, Kirkpatrick P (2006) Abatacept. Nature Rev Drug Discov 5:185–186
doi: 10.1038/nrd1989
Takeshita M, Suzuki K, Kondo Y, Morita R, Okuzono Y, Koga K, Kassai Y, Gamo K, Takiguchi M, Kurisu R, Mototani H, Ebisuno Y, Yoshimura A, Takeuchi T (2019) Multi-dimensional analysis identified rheumatoid arthritis-driving pathway in human T cell. Ann Rheum Dis 78:1346–1356
pubmed: 31167762
doi: 10.1136/annrheumdis-2018-214885
Reiser H, Stadecker MJ (1996) Costimulatory B7 molecules in the pathogenesis of infectious and autoimmune diseases. N Engl J Med 335:1369–1377
pubmed: 8857022
doi: 10.1056/NEJM199610313351807
pmcid: 8857022
Oryoji K, Yoshida K, Kashiwado Y, Tanaka K, Mizuki SI, Tsukamoto H, Kamada K, Akashi K (2018) Shared epitope positivity is related to efficacy of abatacept in rheumatoid arthritis. Ann Rheum Dis 77:1234–1236
pubmed: 28830884
Gottenberg JE, Courvoisier DS, Hernandez MV, Iannone F, Lie E, Canhão H, Pavelka K, Hetland ML, Turesson C, Mariette X, Finckh A (2016) Brief report: association of rheumatoid factor and anti-citrullinated protein antibody positivity with better effectiveness of abatacept: results from the Pan-European registry analysis. Arthritis Rheumatol 68:1346–1352
pubmed: 26815727
doi: 10.1002/art.39595
pmcid: 26815727
Sokolove J, Schiff M, Fleischmann R, Weinblatt ME, Connolly SE, Johnsen A, Zhu J, Maldonado MA, Patel S, Robinson WH (2016) Impact of baseline anti-cyclic citrullinated peptide-2 antibody concentration on efficacy outcomes following treatment with subcutaneous abatacept or adalimumab: 2-year results from the AMPLE trial. Ann Rheum Dis 75:709–714
pubmed: 26359449
doi: 10.1136/annrheumdis-2015-207942
pmcid: 26359449
Harrold LR, Litman HJ, Connolly SE, Kelly S, Hua W, Alemao E, Rosenblatt L, Rebello S, Kremer JM (2017) A window of opportunity for abatacept in RA: is disease duration an independent predictor of low disease activity/remission in clinical practice? Clin Rheumatol 36:1215–1220
pubmed: 28251392
pmcid: 5486472
doi: 10.1007/s10067-017-3588-7
Aletaha D, Neogi T, Silman AJ, Funovits J, Felson DT, Bingham CO III, Birnbaum NS, Burmester GR, Bykerk VP, Cohen MD, Combe B, Costenbader KH, Dougados M, Emery P, Ferraccioli G, Hazes JMW, Hobbs K, Huizinga TWJ, Kavanaugh A, Kay J, Kvien TK, Laing T, Mease P, Ménard HA, Moreland LW, Naden RL, Pincus T, Smolen JS, Stanislawska-Biernat E, Symmons D, Tak PP, Upchurch KS, Vencovský J, Wolfe F, Hawker G (2010) 2010 Rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative. Arthritis Rheum 62:2569–2581
pubmed: 20872595
doi: 10.1002/art.27584
pmcid: 20872595
Knevel R, Lukas C, van der Heijde D, Rincheval N, Combe B, van der Helm-van Mil AH (2013) Defining erosive disease typical of RA in the light of the ACR/EULAR 2010 criteria for rheumatoid arthritis; results of the data driven phase. Ann Rheum Dis 72(4):590–595
pubmed: 23393145
doi: 10.1136/annrheumdis-2012-202778
pmcid: 23393145
Aletaha D, Smolen J (2005) The simplified disease activity index (SDAI) and the clinical disease activity index (CDAI): a review of their usefulness and validity in rheumatoid arthritis. Clin Exp Rheumatol 23(5 Suppl 39):S100–S108
pubmed: 16273793
Xu T, Le TD, Liu L et al (2017) CancerSubtypes: R/Bioconductor package for molecular cancer subtype identification, validation and visualization. Bioinformatics. 33:3131–3133
pubmed: 28605519
doi: 10.1093/bioinformatics/btx378
Monti S et al (2003) Consensus clustering: a resampling-based method for class discovery and visualization of gene expression microarray data. Mach Learn 52:91–118
doi: 10.1023/A:1023949509487
Wang B, Mezlini AM, Demir F, Fiume M, Tu Z, Brudno M, Haibe-Kains B, Goldenberg A (2014) Similarity network fusion for aggregating data types on a genomic scale. Nat Methods 11:333–337
pubmed: 24464287
doi: 10.1038/nmeth.2810
Rousseeuw PJ (1987) Silhouettes: a graphical aid to the interpretation and validation of cluster analysis. J Comput Appl Math 20:53–65
doi: 10.1016/0377-0427(87)90125-7
Gabriel KR (1971) The biplot graphic display of matrices with application to principal component analysis. Biometrika 58:453–467
doi: 10.1093/biomet/58.3.453
Hout MC, Papesh MH, Goldinger SD (2013) Multidimensional scaling. Wiley Interdiscip Rev Cogn Sci 4:93–103
pubmed: 23359318
doi: 10.1002/wcs.1203
Nakamura S, Suzuki K, Iijima H, Hata Y, Lim CR, Ishizawa Y, Kameda H, Amano K, Matsubara K, Matoba R, Takeuchi T (2016) Identification of baseline gene expression signatures predicting therapeutic responses to three biologic agents in rheumatoid arthritis: a retrospective observational study. Arthritis Res Ther 18:159
pubmed: 27435242
pmcid: 4952232
doi: 10.1186/s13075-016-1052-8
Malmström V, Catrina AI, Klareskog L (2017) The immunopathogenesis of seropositive rheumatoid arthritis: from triggering to targeting. Nat Rev Immunol. 17:60–75
pubmed: 27916980
doi: 10.1038/nri.2016.124
Atarashi K, Tanoue T, Shima T, Imaoka A, Kuwahara T, Momose Y, Cheng G, Yamasaki S, Saito T, Ohba Y, Taniguchi T, Takeda K, Hori S, Ivanov II, Umesaki Y, Itoh K, Honda K (2011) Induction of colonic regulatory T cells by indigenous Clostridium species. Science 331:337–341
pubmed: 21205640
doi: 10.1126/science.1198469
Lucchino B, Spinelli FR, Iannuccelli C, et al. Mucosa-environment interactions in the pathogenesis of rheumatoid arthritis. Cells. 2019;8(7)
Bello-Gualtero JM, Lafaurie GI, Hoyos LX, Castillo DM, de-Avila J, Munevar JC, Unriza S, Londoño J, Valle-Oñate R, Romero-Sánchez C (2016) Periodontal disease in individuals with a genetic risk of developing arthritis and early rheumatoid arthritis: a cross-sectional study. J Periodontol 87:346–356
pubmed: 26609697
doi: 10.1902/jop.2015.150455
pmcid: 26609697
Leipe J, Grunke M, Dechant C, Reindl C, Kerzendorf U, Schulze-Koops H, Skapenko A (2010) Role of Th17 cells in human autoimmune arthritis. Arthritis Rheum 62:2876–2885
pubmed: 20583102
doi: 10.1002/art.27622
pmcid: 20583102
van Hamburg JP, Asmawidjaja PS, Davelaar N, Mus AM, Colin EM et al (2011) Th17 cells, but not Th1 cells, from patients with early rheumatoid arthritis are potent inducers of matrix metalloproteinases and proinflammatory cytokines upon synovial fibroblast interaction, including autocrine interleukin-17A production. Arthritis Rheum 63:73–83
pubmed: 20954258
doi: 10.1002/art.30093
pmcid: 20954258
Hickman-Brecks CL, Racz JL, Meyer DM, LaBranche TP, Allen PM (2011) Th17 cells can provide B cell help in autoantibody induced arthritis. J Autoimmun 36:65–75
pubmed: 21075597
doi: 10.1016/j.jaut.2010.10.007
pmcid: 21075597
Mitsdoerffer M, Lee Y, Jäger A et al (2010) Proinflammatory T helper type 17 cells are effective B-cell helpers. Proc Natl Acad Sci U S A 107:14292–14297
pubmed: 20660725
pmcid: 2922571
doi: 10.1073/pnas.1009234107
Arroyo-Villa I, Bautista-Caro M-B, Balsa A, Aguado-Acín P, Nuño L, Bonilla-Hernán MG, Puig-Kröger A, Martín-Mola E, Miranda-Carús ME (2012) Frequency of Th17 CD4+ T cells in early rheumatoid arthritis: a marker of anti-CCP seropositivity. PLoS One 7:e42189
pubmed: 22870298
pmcid: 3411698
doi: 10.1371/journal.pone.0042189
Nie H, Zheng Y, Li R, et al. Phosphorylation of FOXP3 controls regulatory T cell function and is inhibited by TNF-alpha in rheumatoid arthritis. Nat Med 2013;19::322–810
Álvarez-Quiroga C, Abud-Mendoza C, Doníz-Padilla L, Juárez-Reyes A, Monsiváis-Urenda A, Baranda L, González-Amaro R (2011) CTLA-4-Ig therapy diminishes the frequency but enhances the function of Treg cells in patients with rheumatoid arthritis. J Clin Immunol 31:588–595
pubmed: 21487894
doi: 10.1007/s10875-011-9527-5
pmcid: 21487894
Cerutti A (2008) The regulation of IgA class switching. Nat Rev Immunol 8:421–434
pubmed: 18483500
pmcid: 3062538
doi: 10.1038/nri2322
Kokkonen H, Mullazehi M, Berglin E, Hallmans G, Wadell G, Rönnelid J, Rantapää-Dahlqvist S. Antibodies of IgG, IgA and IgM isotypes against cyclic citrullinated peptide precede the development of rheumatoid arthritis Arthritis Res Ther 2011;13: R13
Rantapää-Dahlqvist S, de Jong BA, Berglin E et al (2003) Antibodies against cyclic citrullinated peptide and IgA rheumatoid factor predict the development of rheumatoid arthritis. Arthritis Rheum 48:2741–2749
pubmed: 14558078
doi: 10.1002/art.11223
Ärlestig L, Mullazehi M, Kokkonen H, Rocklöv J, Rönnelid J, Dahlqvist SR (2012) Antibodies against cyclic citrullinated peptides of IgG, IgA and IgM isotype and rheumatoid factor of IgM and IgA isotype are increased in unaffected members of multicase rheumatoid arthritis families from northern Sweden. Ann Rheum Dis 71:825–829
pubmed: 22128080
doi: 10.1136/annrheumdis-2011-200668
Demoruelle MK, Harrall KK, Ho L, Purmalek MM, Seto NL, Rothfuss HM, Weisman MH, Solomon JJ, Fischer A, Okamoto Y, Kelmenson LB, Parish MC, Feser M, Fleischer C, Anderson C, Mahler M, Norris JM, Kaplan MJ, Cherrington BD, Holers VM, Deane KD (2017) Anti-citrullinated protein antibodies are associated with neutrophil extracellular traps in the sputum in relatives of rheumatoid arthritis patients. Arthritis Rheum 69:1165–1175
doi: 10.1002/art.40066
Willis VC, Demoruelle MK, Derber LA, Chartier-Logan CJ, Parish MC, Pedraza IF, Weisman MH, Norris JM, Holers VM, Deane KD (2013) Sputa autoantibodies in patients with established rheumatoid arthritis and subjects at-risk for future clinically apparent disease. Arthritis Rheum 65:2545–2554
pubmed: 23817979
pmcid: 4066465
Wright HL, Moots RJ, Bucknall RC, Edwards SW (2010) Neutrophil function in inflammation and inflammatory diseases. Rheumatology (Oxford) 49:1618–1631
doi: 10.1093/rheumatology/keq045
Bandyopadhyay S, Connolly SE, Jabado O, et al. Identification of biomarkers of response to abatacept in patients with SLE using deconvolution of whole blood transcriptomic data from a phase IIb clinical trial. Lupus Sci Med. 2017;28;4: e000206
Rodriguez FM, Novak ITC (2016) Costimulatory molecules CD80 and CD86 colocalized in neutrophil extracellular traps (NETs). J Immunol Infect Dis 3:103
Sprent J, Surh CD (2002) T cell memory. Annu Rev Immunol 20:551–579
pubmed: 11861612
doi: 10.1146/annurev.immunol.20.100101.151926
Emery P, Durez P, Dougados M, Legerton CW, Becker JC, Vratsanos G, Genant HK, Peterfy C, Mitra P, Overfield S, Qi K, Westhovens R (2010) Impact of T-cell costimulation modulation in patients with undifferentiated inflammatory arthritis or very early rheumatoid arthritis: a clinical and imaging study of abatacept (the ADJUST trial). Ann Rheum Dis 69:510–516
pubmed: 19933744
doi: 10.1136/ard.2009.119016
Al-Laith M, Jasenecova M, Abraham S et al (2019) Arthritis prevention in the pre-clinical phase of RA with abatacept (the APIPPRA study): a multi-centre, randomised, double-blind, parallel-group, placebo-controlled clinical trial protocol. Trials. 20:429
pubmed: 31307535
pmcid: 6633323
doi: 10.1186/s13063-019-3403-7
Gur C, Porgador A, Elboim M, Gazit R, Mizrahi S, Stern-Ginossar N, Achdout H, Ghadially H, Dor Y, Nir T, Doviner V, Hershkovitz O, Mendelson M, Naparstek Y, Mandelboim O (2010) The activating receptor NKp46 is essential for the development of type 1 diabetes. Nat Immunol 11:121–128
pubmed: 20023661
doi: 10.1038/ni.1834
pmcid: 20023661
Shegarfi H, Naddafi F, Mirshafiey A (2012) Natural killer cells and their role in rheumatoid arthritis: friend or foe? ScientificWorldJournal. 2012:491974
pubmed: 22547986
pmcid: 3322405
doi: 10.1100/2012/491974
Yamin R, Berhani O, Peleg H, Aamar S, Stein N, Gamliel M, Hindi I, Scheiman-Elazary A, Gur C (2019) High percentages and activity of synovial fluid NK cells present in patients with advanced stage active rheumatoid arthritis. Sci Rep 9:1351
pubmed: 30718650
pmcid: 6361912
doi: 10.1038/s41598-018-37448-z
Pradier A, Papaserafeim M, Li N, et al. Small-molecule immunosuppressive drugs and therapeutic immunoglobulins differentially inhibit NK cell effector functions in vitro. Front Immunol. 2019;10;10: 556
Kim TJ, Kim N, Kang HJ, Kim EO, Kim ST, Ahn HS, Bluestone JA, Lee KM (2010) FK506 causes cellular and functional defects in human natural killer cells. J Leukoc Biol 88:1089–1097
pubmed: 20671192
pmcid: 6608018
doi: 10.1189/jlb.0310148
Neudoerfl C, Mueller BJ, Blume C et al (2013) The peripheral NK cell repertoire after kidney transplantation is modulated by different immunosuppressive drugs. Front Immunol 4:46
pubmed: 23450662
pmcid: 3584176
doi: 10.3389/fimmu.2013.00046
Yun H, Xie F, Delzell E, Levitan EB, Chen L, Lewis JD, Saag KG, Beukelman T, Winthrop KL, Baddley JW, Curtis JR (2016) Comparative risk of hospitalized infection associated with biologic agents in rheumatoid arthritis patients enrolled in Medicare. Arthritis Rheumatol. 68:56–66
pubmed: 26315675
doi: 10.1002/art.39399
pmcid: 26315675
Yokoyama, W. M., Thompson, M. L. and Ehrhardt, R. O. Cryopreservation and thawing of cells. Curr Protoc Immunol Appendix 3, 3G
Verstappen GM, Meiners PM, Corneth OBJ, Visser A, Arends S, Abdulahad WH, Hendriks RW, Vissink A, Kroese FGM, Bootsma H (2017) Attenuation of follicular helper T cell-dependent B cell hyperactivity by abatacept treatment in primary Sjögren’s syndrome. Arthritis Rheumatol 69:1850–1861
pubmed: 28564491
doi: 10.1002/art.40165
pmcid: 28564491
Rao DA, Gurish MF, Marshall JL, Slowikowski K, Fonseka CY, Liu Y, Donlin LT, Henderson LA, Wei K, Mizoguchi F, Teslovich NC, Weinblatt ME, Massarotti EM, Coblyn JS, Helfgott SM, Lee YC, Todd DJ, Bykerk VP, Goodman SM, Pernis AB, Ivashkiv LB, Karlson EW, Nigrovic PA, Filer A, Buckley CD, Lederer JA, Raychaudhuri S, Brenner MB (2017) Pathologically expanded peripheral T helper cell subset drives B cells in rheumatoid arthritis. Nature. 542:110–114
pubmed: 28150777
pmcid: 5349321
doi: 10.1038/nature20810
Chen Z, Bozec A, Ramming A, Schett G (2019) Anti-inflammatory and immune-regulatory cytokines in rheumatoid arthritis. Nat Rev Rheumatol 15:9–17
pubmed: 30341437
doi: 10.1038/s41584-018-0109-2